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INTRODUCTION
The serine/arginine-rich splicing factor (SRSF)
family comprises at least 12 conserved and struc-
turally related RNA-binding proteins (SRSF1 to
SRSF12) (1). SRSF3 (also known as SRp20) binds
cis -acting RNA elements through an N-terminal
RNA recognition motif (RRM), and a C-terminal re-
gion enriched in Ser-Arg dipeptides (SR domain)
mediates interactions with other proteins for regu-
lation of both constitutive and alternative splicing of
pre-mRNA (2). In addition, several lines of recent
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evidence suggest that SR protein family also regu-
lates RNA elongation (3), transport (4), and transla-
tion (5), suggesting a wide-ranging role in gene ex-
pression. In addition, SRSF3 is overexpressed in hu-
man ovarian cancer, and its knockdown results in
apoptosis of ovarian cancer cells (6). Recently, we
have shown that reduction of SRSF3 causes G1 cell
cycle arrest and apoptosis in colon cancer cells (7).
These findings suggest that SRSF3 may be one of
the essential factors for regulation of cell fate.
The human SRSF3 gene is composed of 7 ex-
ons and generates two mRNA isoforms. Like other
SRSF family member genes, the human SRSF3 gene
contains an element of extreme sequence conser-
vation, termed “ultraconserved element” (UCE).
SRSF3 contains a 577-bp UCE that includes entire
exon 4, and this exon 4 has multiple premature
termination codons (PTCs). A major SRSF3 mRNA
isoform encoding a functional full-length SRSF3
protein (SRSF3-FL) excludes this exon 4. Alterna-
tive splicing of SRSF3 pre-mRNA produces another
mRNA isoform consisting of entire 7 exons. This
PTC-containing SRSF3 isoform (SRSF3-PTC ) is
considered to be degraded through the nonsense-
mediated mRNA decay (NMD) system, a surveil-
lance mechanism that decomposes PTC-containing
mRNAs. However, it was reported that SRSF3-PTC
mRNA was translated into a truncated SRSF3 pro-
tein (SRSF3-TR) partially lacking RS domain in the
murine B-cell lymphoma K46 cells (8). We also
found that colon cancer cells (HCT116) induced
SRSF3-TR in response to sodium arsenite (unpub-
lished observations). At present, however, the bio-
logical function of SRSF3-TR is unknown.
In this study, we established Flp-In-293 cells
stably expressing SRSF3-TR, and showed that
SRSF3-TR facilitated cell growth through up-regu-
lating c-Jun expression.
MATERIALS AND METHODS
Cell culture and cell counting
Flp-In-293 cells (Invitrogen, Carlsbad, CA) were
maintained in high-glucose Dulbecco’s modified
Eagle’s medium (Nacalai tesque, Kyoto, Japan) sup-
plemented with 10% (v/v) heat-inactivated fetal calf
serum, 2 mM l-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin in a humidified atmosphere
of 5% CO2 in air. Numbers of growing cells were
counted manually using a hematocytometer.
Plasmid construction
Using a cDNA library prepared from a human
colon cancer cell line (HCT116), the human
SRSF3-PTC mRNA (Ensembl Transcript ID :
ENST00000477442) were amplified by PCR using
a primer set : 5’ -AAAAAAGGATCCATGCATCGT-
GATTCCTGTCCATTG-3’ (forward, BamHI site is
underlined) and 5’ -AAAAAAGATATCCTATTTCC-
TTTCATTTGACCTAGA-3’ (reverse, EcoRV site
is underlined). The amplified product was cloned
into the mammalian expression vector pCMV-3Tag
(pCMV-3Tag/SRSF3-TR ; Stratagene, La Jolla, CA).
FLAG was appended to the NH2 termini of SRSF3.
Subsequently, PCR was performed using the pCMV-
3Tag/SRSF3-TR plasmid as the template and the
following primer set : 5’ -AAAAAAGGTACCGCCA-
CCATGGATTACAAGGA-3’ (forward, KpnI site is
underlined) and the same reverse primer used for
amplification of SRSF3-PTC mRNA. The amplified
products were cloned into the pcDNA5/FRT vector
(pcDNA5/FRT-3xFLAG-SRSF3-TR). All constructs
were confirmed to have the expected sequence by
DNA sequencing. The plasmid was transfected us-
ing FuGENE HD (Promega, Madison, WI) accord-
ing to the manufacturer’s instructions.
Establishment of a cell line stably expressing
SRSF3-TR
Flp-In-293 cells were co-transfected with the
pcDNA5/FRT-3xFLAG-SRSF3-TR vector and a Flp
recombinase expression plasmid pOG44 accord-
ing to the manufacturer’s protocol of the Flp-In sys-
tem (Invitrogen). A single colony resistant to hygro-
mycin B (Invitrogen) was selected and subcultured.
Selection of positive colonies (293/SRFS3-TR) was
performed by Western blotting using an anti-SRSF3
antibody. Flp-In-293 cells were transfected with
pcDNA5/FRT-3xFLAG-mock and pOG44 vectors
(293/mock cells) and used as a control.
Quantitative real-time reverse transcription-PCR
(qPCR)
Total RNA was extracted from 293/SRSF3-TR
or 293/mock cells using an RNAiso plus (Takara,
Otsu, Japan). One microgram of isolated RNA was
reverse-transcribed using ReverTra Ace reverse
transcriptase (TOYOBO, Osaka, Japan). Primer
sequences are shown in Table 1. Target mRNA
levels were measured using SYBR green master mix
and the 7500 real-time system (Applied Biosys-
tems, Foster City, CA). Glyceraldehyde 3-phosphate
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dehydrogenase (GAPDH) mRNA and 18S were meas-
ured as internal controls for normalization. Us-
ing the ΔΔCt method, data are presented as fold
changes in mRNA levels relative to those in 293/
mock cells.
Western blotting
Whole-cell lysates were prepared in RIPA buffer
(10 mM Tris-HCl, pH 7.4 ; 150 mM NaCl ; 1 mM
EDTA ; 1 mM DTT ; 0.1% sodium dodecyl sulfate ;
1% Nonidet P-40) containing a protease and phos-
phatase inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO). The extracted proteins were separated by so-
dium dodecyl sulfate-polyacrylamide gel electropho-
resis and transferred to a polyvinylidene difluoride
membrane (BioRad, Hercules, CA). After blocking
with 5% non-fat dry milk, the membranes were incu-
bated overnight at 4with a mouse monoclonal
anti-SRSF3 (1 : 1000 dilution, Sigma-Aldrich), anti-
FLAG (1 : 1000, Sigma-Aldrich), anti-cyclin D1 (1 :
1000, Cell Signaling Tech., Danvers, MA), anti-
cyclin D3 (1 : 1000, Cell Signaling Tech.), anti-cy-
clin E (1 : 1000, Santa Cruz Biotech., Santa Cruz,
CA), anti-CDC25A (1 : 1000, Cell Signaling Tech.),
anti-E2F1 (1 : 1000, Cell Signaling Tech.), anti-c-
Jun (1 : 1000 ; Cell Signaling Tech.), anti-Sp1 (1 :
1000, Sigma-Aldrich), or anti-GAPDH (1 : 5000 ;
Santa Cruz Biotech.) antibody. Following incuba-
tion with an appropriate secondary antibody for 1 h
at room temperature, bound antibodies were de-
tected with an ECL or ECL Prime Western Blot-
ting Detection System (GE Healthcare, Piscataway,
NJ). The membrane was re-blotted using an anti-
GAPDH antibody as a loading control.
Promoter activity assay
The 5’ flank of the human JUN gene was cloned
into the pGL3-basic luciferase reporter vector
(Promega). In brief, the first PCR was performed
using the human genomic DNA as a template. The
JUN proximal promoter region (from -1,266 to +170
bp) was amplified using the following primer set :
5’ -AAAAAGGTACCTTACATGTGTCTAGCGCTTC-
3’ (forward) and 5’ -AAAAACTCGAGGGGAGCCA-
CAGGCGCTAGCTCT-3’ (reverse). Subsequently,
the amplified product was used as a template to gen-
erate deletion constructs consisting of the -798 to
+170 bp, -331 to +170 bp, and -32 to +170 bp re-
gions using the same reverse primer and one of the
following forward primers : 5’ -AAAAAGGTACCTC-
TCGGCTTCTACGAGCAGC-3’ for -798 to +170 bp,
5’ -AAAAAGGTACCCCAAGACGTCAGCCCACAA-
TG-3’ for -331 to +170 bp and 5’ -AAAAAGGTACC-
AGCCAATGGGAAGGCCTTG-3’ for -32 to +170
bp. The amplified products were subcloned into the
pGL3-basic vector using KpnI and SacI restriction
sites. Using FuGENE HD (Promega), pGL-3 lu-
ciferase constructs (100 ng) and pRL-CMV vector
(50 ng) were co-transfected into 293/mock or 293/
SRFS3-TR cells (7.5 x 104 cells) growing on 24-well
plates. Twenty-four hours after the transfection, cells
were harvested, and the firefly and renilla luciferase
activities were measured using the Dual-Luciferase
Reporter Assay System (Promega).
RESULTS
Effect of SRSF3-TR on cell growth
To disclose novel function(s) resided in a trun-
cated SRSF3 (SRSF3-TR), we established a cell
line stably expressing FLAG-tagged SRSF3-TR us-
ing the Flp-In system (Invitrogen). After transfec-
tion of Flp-In-293 cells with the vectors encoding
3xFLAG-SRSF3-TR and Flp recombinase, a posi-
tive clone (293/SRSF3-TR) was selected. The 293/
SRSF3-TR cells stably expressed similar amounts
of both endogenous SRSF3-FL and FLAG-tagged
SRSF3-TR (Figure 1A). The stable expression of
Table 1. Primer sets used for quantitative real - time RT-PCR
(qPCR)
Targets Primer Sequences (5’ - 3’)
SRSF3-PTC forward TCCACCTCGTCGCAGAGTCACCATC
reverse TCATGTGAAACGACACCAGCCAAGC
CCND1 forward GAAGATCGTCGCCACCTG
reverse GACCTCCTCCTCGCACTTCT
CCND3 forward GCTTACTGGATGCTGGAGGTA
reverse AAGACAGGTAGCGATCCAGGT
CCNE1 forward GGCCAAAATCGACAGGAC
reverse GGGTCTGCACAGACTGCAT
CDC25A forward ATCTCTTCACACAGAGGCAGAA
reverse CCCTGGTTCACTGCTATCTCTT
E2F1 forward TCCAAGAACCACATCCAGTG
reverse CTGGGTCAACCCCTCAAG
JUN forward CAGGTGGCACAGCTTAAACA
reverse GTTTGCAACTGCTGCGTTAG
GAPDH forward AGCCACATCGCTCAGACAC
reverse GCCCAATACGACCAAATCC
18S forward CCCTATCAACTTTCGATGGTAGTCG
reverse CCAATGGATCCTCGTTAAAGGATTT
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SRSF3-TR did not change endogenous SRSF3-FL
levels (Figure 1A). Unexpectedly, SRSF3-TR-ex-
pressing cells showed significantly accelerated
growth, compared with control 293/mock cells
(Figure 1B).
Effects of SRSF3-TR on expression of genes crucial
for G1 to S phase transition
In a previous study, we showed that SRSF3 knock-
down caused G1 cell cycle arrest through inhibi-
tion of cyclin D/CDK4/6 activation and reduction
of E2F1 expression (7). Based on the data, we com-
pared mRNA and protein levels of cyclins (D1, D3,
and E1), E2F1, and CDC25A between 293/SRSF3-
TR and 293/mock cells. As shown in Figure 2,
SRSF3-TR-expressing cells significantly up-regu-
lated expression of CCND1 , CCND3 , CCNE1 , E2F1 ,
and CDC25A mRNAs (Figure 2A) and increased
amounts of cyclin D1, cyclin D3, CDC25A, and E2F1
(Figure 2B). The first kinase complexes to be-
come active in G1 phase are cyclin D/CDK4/6 that
initiate phosphorylation of retinoblastoma (RB)
proteins and release E2F1 from the RB-repressor
complex, permitting transcription essential for the
G1/S transition. Induction of cyclin D1 is important
for the activation of cyclin D/CDK4/6. We, there-
fore, focused on the mechanism how SRSF3-TR
increased expression of cyclin D1. Several lines of
evidence suggest that c-Jun is one of the crucial fac-
tor for cyclin D1 expression (9, 10). In fact, 293/
SRSF3-TR cells increased JUN mRNA (Figure 3A)
and c-Jun protein (Figure 3B) levels, compared
with 293/mock cells. We also confirmed that the
stable expression of SRSF3-TR did not change the
stability of JUN mRNA, suggesting that SRSF3-TR
might activate transcription of the JUN gene.
Effects of SRSF3-TR on JUN promoter activity
To test whether SRSF3-TR regulated c-Jun ex-
pression at the transcriptional level, we cloned the
5’ -flank of JUN (from -1,266 to +170 bp), and 293/
SRSF-TR or 293/mock cells were transfected with
a luciferase reporter construct containing -1,266/
+170, -798/+170, -331/+170, or -32/+170 bp re-
gion of the human JUN promoter (Figure 5A). As
shown in Figure 4A, 293/SRSF3-TR cells signifi-
cantly increased the luciferase reporter activity of
the -1,266/+170 and -798/+170 bp regions of the
JUN promoter, compared with 293/mock cells. The
-331/+170 bp construct partially reduced the pro-
moter activity in 293/SRSF3-TR cells, and the -32/
+170 bp region almost completely lost the promoter
activity (Figure 4A). The -331/-32 bp region con-
tains two AP-1-binding sites (-190 to -183 and -71 to
-64) (Figure 4C), and the proximal AP-1-binding
Figure 2. Expression of G1 to S phase transition regulators in
293/SRSF3-TR cells.
(A) Levels of CCND1 , CCND3 , CCNE1 , CDC25A , and E2F1
mRNAs in 293/SRSF3-TR cells were measured by qPCR us-
ing GAPDH mRNA as an endogenous quantity control. Val-
ues (meansSD, n=3) are expressed as fold changes, com-
pared with those of 293/mock cells. *P0.05 by ANOVA and
Bonferroni test. (B) Amounts of cyclins (D1, D3, and E1),
CDC25A, and E2F1 proteins in these cells were measured by
Western blotting using GAPDH as a loading control.
Figure 1. Cell proliferation of 293/SRSF3-TR cells.
(A) Flp-In-293 cells stably expressing FLAG tagged-SRSF3-TR
(293/SRSF3-TR) or mock (293/mock) were established using
the Flp-In system as described in Materials and Methods. Whole-
cell lysates were prepared from them and subjected to Western
blotting using the SRSF3 antibody. GAPDH was served as a load-
ing control. (B) Numbers of growing cells in 35 mm cloture
dishes were counted on day 4 after plating. Values represent
meansSD, n=3. *P0.05 by ANOVA and Bonferroni test.
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Figure 3. Up-regulation of c-Jun expression in 293/SRSF3-TR cells.
(A) Levels of JUN mRNA in 293/SRSF3-TR cells were measured by qPCR using GAPDH mRNA as an endogenous quantity control. Val-
ues (meansSD, n=4) are expressed as fold changes, compared with those of 293/mock cells. *P0.05 by ANOVA and Bonferroni
test. (B) Amounts of c-Jun proteins were measured by Western blotting using GAPDH as a loading control. (C) To compare the stability
of JUN mRNA between 293/mock ( ) and 293/SRSF3-TR () cells, both cells were incubated with 2.5 μg/ml actinomycin D for the
indicated times. Amounts of JUN mRNA remained were measured by qPCR. Amounts of 18S were also measured as a control.
Figure 4. JUN promoter activity in 293/SRSF3-TR cells.
(A) Luciferase reporter plasmids (pGL3) driven by 1,266-, 798-, 331-, 32-bp JUN promoter fragments were transfected into 293/
SRSF3-TR and 293/mock cells. After transfection for 24 h, these cells were harvested, and luciferase activity was measured using
the Dual -Luciferase Reporter Assay System. Values are expressed as fold changes (meansSD, n=6). *P0.05 by ANOVA and
Bonferroni test. (B) Amounts of Sp-1 proteins were measured by Western blotting using GAPDH as a loading control. (C) Nucleo-
tide sequence of the 5’ - flanking region of the human JUN gene. Putative binding sites for Sp-1, CTF and AP-1 are indicated with
underlines. Sp-1 predicted binding sites between -798 and -332 bp based on the JASPER database (relative profile score threshold
85%) are shown by a square. Putative transcription initiation site is indicated by a bent arrow.
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site is responsible for trans -activation of the JUN
promoter by its gene product (11). Sp-1 is also
known as a crucial transcription factor for JUN (12),
and several Sp-1-binding sites are distributed in
both -331/-32 bp and -798/-332 bp regions. More-
over, 293/SRSF3-TR significantly induced Sp-1
(Figure 4B), suggesting that multiple cis elements
distributed in the -798/-32 bp region might be in-
volved in the SRSF3-TR-mediated JUN promoter
activity.
DISCUSSION
Alternative splicing is important for generation
of protein isoform diversity and for regulation of
gene expression program. At the same time, how-
ever, up to one-third of alternative splicing of hu-
man genes generates PTC-containing mRNAs (13).
All SRSF family member genes produce PTC-con-
taining splice variants, which is coincided with the
presence of UCEs (14). To avoid production of the
C-terminally truncated proteins which may have
potential dominant-negative or gain-of-function,
PTC-containing mRNAs are expected to be de-
graded by NMD. However, several lines of evidence
have shown that NMD activity is often inhibited
by stresses, such as hypoxia, amino acid starvation,
and generation of reactive oxygen species (15-17).
Moreover, it has been shown that the impairment
of NMD is involved in the oncogenic mechanism
(18). In fact, several cancer cell lines (HCT116,
RKO, and HeLa cells) constitutively expressed sig-
nificant amounts of the SRSF1 PTC variant. For
example, HCT116 cells expressed the SRSF1 PTC
variant nearly equivalent to the major isoform (data
not shown). These PTC variants are believed not
to be translatable, whereas SRSF3-TR was docu-
mented to be translated from SRSF3-PTC mRNA
(8). We also found that treatment of HCT116 cells
with sodium arsenite induced SRSF3-TR possibly
through inhibiting NMD (unpublished observa-
tions). The inclusion of exon 4 to mature SRSF3
mRNA was reported to occur under serum starva-
tion (8), and the biological significance of exon 4-
inclusion is considered to be an auto-regulatory
feedback loop by SRSF3 itself (19).
To uncover unknown functions of SRSF3-TR, we
established a cell line stably expressing SRSF3-TR
using the Flp-In system, and found that SRSF3-TR-
expressing cells (293/SRSF3-TR) significantly ac-
celerated their growth, compared with control cells
(293/mock). As to the mechanism for the acceler-
ated cell growth, 293/SRSF3-TR significantly in-
creased mRNA and protein levels of essential regu-
lators for the G1 to S phase transition, which in-
cluded cyclin D1, cyclin D3, CDC25A, and E2F1. c-
Jun is required for progression through the G1
phase, the mechanism by which involves transcrip-
tional control of the cyclin D1 gene (CCND1). We
also confirmed that SRSF3-TR-expressing cells sig-
nificantly increased expression of JUN mRNA and
induced c-Jun protein without any growth stimulus.
c-Jun positively regulates cell proliferation through
the induction of CCND1 transcription and the re-
pression of tumor suppressor gene expression and
function (20). The regulatory elements crucial for
the human CCND1 transcription contain two AP-1
binding sites and several AP-1 proteins including
c-Jun and c-FOS were shown to bind these sites
and suggested to stimulate CCND1 transcription
(21-23). Along with this line, 293/SRSF3-TR cells
exhibited a significantly augmented promoter activ-
ity of JUN . The proto-oncogene JUN is positively
autoregulated by its product, c-Jun/AP-1 (11). It
was reported that two AP-1-binding sites (-182 and
-64) of the JUN promoter were important for basal
activity and dexamethasone-mediated repression of
the JUN promoter (24). The proximal -71 to -64 bp
region is responsible for the autoregulation of the
JUN promoter activity (11). Our luciferase reporter
assay also indicated the importance of the -331 to
-32 bp region for both basal and SRSF3-TR-depend-
ent activities of the JUN promoter. At the same
time, however, our results implicated that there
might be SRSF3-TR responsive element(s) in the
-798 to -332 bp region. In addition to c-Jun, Sp-1
plays an essential role for basal expression of JUN
(12). The -331/-32 bp region of the JUN promoter
contains one Sp-1-binding site, and several putative
Sp-1-binding sites are scattered in the -798 to -332
bp region. Moreover, Sp-1 was induced in 293/
SRSF3-TR cells. Thus, multiple trans factors and cis
elements appear to be involved in the SRSF3-TR-
mediated transcription of JUN . Further studies are
needed to elucidate the mechanism how SRSF3-TR
regulates c-Jun expression.
Although the mechanism how SRSF3-TR regu-
lates c-Jun expression remains to be elucidated, our
results suggest that a truncated SRSF3 derived from
a PTC-containing splice variant of the SRSF3 gene
may have a mitogenic property. NMD was often in-
hibited under certain conditions such as hypoxia
and oxidative stress. Cancer tissues are exposed
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to similar microenviromental conditions, and it has
been shown that the impairment of NMD is in-
volved in the oncogenic mechanism (18). In such
situations, SRSF3-TR could be induced and might
participate in abnormal cell growth. Further studies
are needed to fully elucidate the molecular mecha-
nism for the SRSF3-TR-mediated acceleration of
cell growth.
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